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Estrogen receptor pharmacologyOver the past two decades, our understanding of estrogen receptor physiology in mammals widened
considerably as we acquired a deeper appreciation of the roles of estrogen receptor alpha and beta (ERα and
ERβ) in reproduction as well as in bone and metabolic homeostasis, depression, vascular disorders,
neurodegenerative diseases and cancer. In addition, our insights on ER transcriptional functions in cells
increased considerably with the demonstration that ER activity is not strictly dependent on ligand availability.
Indeed, unliganded ERs may be transcriptionally active and post-translational modiﬁcations play a major role
in this context. The ﬁnding that several intracellular transduction molecules may regulate ER transcriptional
programs indicates that ERs may act as a hub where several molecular pathways converge: this allows to
maintain ER transcriptional activity in tune with all cell functions. Likely, the biological relevant role of ER was
favored by evolution as a mean of integration between reproductive andmetabolic functions. We here review
the post-translational modiﬁcations modulating ER transcriptional activity in the presence or in the absence
of estrogens and underline their potential role for ER tissue-speciﬁc activities. In our opinion, a better
comprehension of the variety of molecular events that control ER activity in reproductive and non-
reproductive organs is the foundation for the design of safer and more efﬁcacious hormone-based therapies,
particularly for menopause. This article is part of a Special Issue entitled: Translating Nuclear receptors from
health to disease.slating Nuclear receptors from
eurodegenerative Diseases and
ilan, Via Balzaretti 9, 201313,
8290.
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
In all metazoans, the ability of nuclear receptors (NR) to regulate
large transcription gene programs provides a critical strategy for the
control of complex physiological processes such as reproduction,
development and homeostasis; this may explain why dysregulation of
NR functions is associated with a large variety of diseases.
Among the NR gene family, the two mammalian estrogen
receptors, estrogen receptor alpha (ERα, ESR1, NR3A) and estrogen
receptor beta (ERβ, ESR2, NR3b) [1], are phylogenetically very ancient
as are expressed in non-vertebrates as well as in vertebrates [2]. The
complexity of ER mechanisms of activation and functions suggests
that during the evolution these proteins were implicated in a variety
of functions which stratiﬁed with time and are still functioning in
vertebrates. Structurally similar to all nuclear receptors, ERs are
composed of six functional domains (named A-F) [3] and are
generally classiﬁed as ligand-dependent transcription factors because,
after the association with their speciﬁc ligands, they bind speciﬁcgenomic sequences (named Estrogen Responsive Elements, or EREs)
and interact with co-regulators tomodulate the transcription of target
genes. Several lines of evidence showed that the unliganded ER may
be transcriptionally activated by selected post-translational modiﬁ-
cations (PTM). In addition to their capability to modulate the activity
of selected promoters directly, the liganded or unliganded ERs
regulate several intracellular pathways by molecular interference
with other signaling molecules present in the nucleus (e.g. transcrip-
tion factors like NF-Kb or AP-1) or in the cytoplasm (e.g. IP3K, G
proteins and others) [4]. Because of their widespread expression and
the variety of interactions with extracellular as well as intracellular
signalingmolecules it is conceivable that ERsmay help to adjust single
cell functions in relation with the overall body homeostasis. Indeed,
ER ablation or dysregulation is associated with altered functions of
several systems including the reproductive [5], cardiovascular [6,7],
skeletal [8,9] immune [10] and nervous systems [4,11,12].
2. Mechanisms of ER transcriptional activation
2.1. Hormone-dependent
Transcriptional activation by ERs is a multistep process, occurring
in a sequential order, that requires the interaction of the receptor with
a wide variety of primary and secondary enzymatic activities to obtain
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ERs are generally maintained inactive by speciﬁc inhibitory proteins
which must be removed to enable the ER-dependent transcriptional
activity. Ligand-operated transcription by ERs is initiated by the
binding of estrogenic compounds to the inactive ER-chaperon
complex. The ligand binding occurs at the ER hormone binding
domain (HBD) located in the C-terminus E region. The HBD consists of
12 α-helices arranged as a three-layered anti-parallel α-helical
sandwich that forms the hydrophobic site to which the ligand binds.
The accommodation of the ligand causes a reorientation of helix 12
toward the opening of the HBD allowing helices 3,5 and 12 to generate
a novel activation function (AF) domain consisting of a hydrophobic
grove on the LBD binding surface [13,14]. The ligand-dependent
allosteric alteration mediates the dissociation of ER from its
chaperones/nuclear matrix-associated binding proteins [15] unmask-
ing the domains for receptor dimerization, nuclear localization,
binding to the EREs (DBD, C region) and binding to other transcription
proteins. Thus, by shedding the chaperons, ER enhances its ability to
homo- or hetero-dimerize [16], changes the dynamics of partitioning
between nuclear matrix and chromatin [17] and increases the
intramolecular interactions thus strengthening the stability of ER
interactions [18] with the ERE and the co-activators; this ultimately
leads to the recruitment of the enzymatic complex necessary for
transcription initiation.
Once bound to the DNA, ER transcriptional activity is dependent on
two activating functions (AFs): AF-1 in the receptor's N-terminus A/B
region and the AF-2 in the E region. The AF-1 operates in a ligand-
independent mode, while AF-2 is ligand-dependent [19,20]. Although
the two domains can function independently, the maximal ER
transcriptional activity is achieved when there is synergy among the
two AFs [21]. These sites are ﬁeld of interaction for a large number of
co-activator proteins. The presence of co-activators facilitates the
interactions between the NR and the transcriptional machinery. The
co-activators bind to the ligand-activated receptor through a highly
conserved signature motif LXXLL termed the “nuclear receptor box”
[22]. Extensive studies of the binding afﬁnities of the members of
the p160 family of co-activators and other chromatinmodiﬁers (e.g. the
histone acetyltransferase p300) indicate that p160 proteins (steroid
receptor co-activators: SRC-1, SRC-2 and SRC-3) act as bridging proteins
for the assembly of the complex regulatory framework required for the
chromatinmodiﬁcations and synthesis of theprimary transcript [23,24].
The kinetics of the ERα binding to the pS2 promoter have been
extensively studied in MCF-7 cells where the punctual interactions of
the liganded receptor with all the components of the transcriptional
apparatus as well as with co-regulators were described [17,25,26]. The
ERα–ERE association facilitates the recruitment of very speciﬁc
enzymatic activities necessary for chromatin remodeling (e.g. histones
H3 K14 and H4 R3 acetylases or HATs, and methylases or HMTs) and,
witha short lagperiod, the components of thepreinitiation complexand
Pol II. DNA transcription initiates with cycles of about 40–45 min in
which the system becomes periodically refractory to the activated ERα
with alternate activating and repressing epigenetic processes. In these
cycles, ERα undergoes protein modiﬁcations leading to disassembling
of the transcription complex and receptor degradation. This oscillations
at the promoter is believed to be necessary to poise ER-dependent
transcriptional activity to the mutable requirements of the cell
metabolism [17].
A constellation of PTM (phosphorylation, acetylation, methylation,
sumoylation) regulates ER activities prior and after its binding to the
DNA modulating its ability to operate also in relation to the cell and
whole organisms cues (Table 1). For instance, ERα phosphorylation
may occur at 10 different serine/threonine/tyrosine residues and was
shown to be necessary for receptor dimerization and recruitment of
speciﬁc transcription factors such as p160 co-regulators and chroma-
tin remodeling enzymes [27,28]. In addition, phosphorylation of Ser
305 was shown to facilitate the receptor acetylation required for thefacilitation of DNA binding and ligand-induced transcriptional activity
[29]. Interestingly, acetylation lys 266–268 increases ER activity,
whereas the same PTM at Lys 299, 302 and 303 is associated with a
decrease of ER-dependent transcription [30,31]. ERα palmitoylation
anchors a pool of ERα to the plasma membrane where it may interact
with other signaling proteins (such as Src or PI3K) [32]. Methylation
in the hinge region of ERα (Lys 302 induced by the lysine methyl
transferase Set7) increases the receptor stability [33], however when
the methylation of ERα occurs at the Arg 260 residue, it facilitates the
interactions with other signaling molecules such as Src or PI3K [34].
ERα ubiquitination may occur both on inactive receptor and on the
receptor actively engaged in transcription. In the ﬁrst case, it is
responsible for the clearance of themisfolded protein; in the second, it
causes inhibition of ERα degradation and decreases ERα [35,36]
transcriptional activity. This latter observation indicates that the
stabilization of the protein may be relevant for the regulation of the
efﬁciency of ER-dependent transcription. Finally, ERαmay be target of
small ubiquitin-like modiﬁers (SUMO) enzymes that induce the
covalent attachment of SUMO to Lys residues, this modiﬁcation
generally does not induce protein degradation, but facilitates in-
teractions with other proteins. In the case of ERα, sumoylation occurs
at two Lys in the hinge region (Lys 266 and Lys 268) following
activation by the ligand and their mutation results in decreased
receptor activity [37].
2.2. Hormone-independent
PTM of ERs are relevant for the transcriptional activation of
unliganded ER as demonstrated by several groups following the initial
observation by O'Malley's group who ﬁrst reported that, in the
absence of the cognate ligand, the progesterone receptor could be
transcriptionally activated by phosphorylation [66]. ERα was shown
to be activated by epidermal growth factor (EFG) [67]; IGF-1 [43,68]
and neurotransmitters like dopamine, via cAMP/PKA activation
[69,70]. However, in spite of the solid evidence demonstrating the
possibility of ER transcriptional activation in the absence of ligands,
the characterization of the mechanisms involved in this process
has proven quite difﬁcult. Initial studies in transfected cells pointed
to the relevance of selected kinases (MAPK, PKA and p21 ras/ERK)
[42,60,71–73] for ER activation; furthermore, the use of mutants of
ERα showed that in each cell system speciﬁc ER phosphorylation sites
were necessary for the unliganded ER activity (e.g. Ser 118 in COS-1
cells and Tyr 537 in neuroblastoma cells) [45]. This observation
indicated that unliganded ER activation might fulﬁll a variety of cell-
speciﬁc functions. Yet, in some cases, the direct phosphorylation of
ERα was reported to be insufﬁcient by itself for the transcriptional
activation of the receptor even if allowed the recruitment of co-
regulators and splicing factors [46]. More recently, in MCF-7 cells it
was shown that for PKA-induced activation of the unliganded ERα the
direct phosphorylation of the receptor is dispensable, but the
phosphorylation of the coactivator-associated arginine methyltrans-
ferase 1 (CARM1) at a single serine is sufﬁcient for its direct binding to
the HBD of the receptor and its activation [74].
Several studies have underlined the importance of unliganded ERα
activation in mammalian physiology: it was shown that growth
hormone/neurotransmitter-dependent activation of ER is required in
reproductive and non-reproductive organs (such as IGF-1 growth of
the uterine epithelium or neonatal behavior modulated by dopamine
in speciﬁc brain areas) [75] and that aberrant mechanisms of
unliganded ERα activation may underpin the development of ER-
positive cancer cells towards resistance to endocrine therapy [76]. The
use of ERE-Luc reporter mice further underscored the concept of
independence of ER activity from circulating estrogens, rather
showing that activation of ERs by other signaling pathways such as
growth factors and their intracellular signal transducers may play the
dominant role in non-reproductive organs like bone and brain [77]. It
Table 1
ER post-translational modiﬁcations.
PTM Domain Kinase Function Ref.
ERα phosphorylation
Ser 102, 104, 106 N-terminus (AF-1) glycogen synthase kinase-3 (GSK3) transcription activation [38]
Ser 102, 104, 106 Cyclin A CDK2 AF-2 independent transcription activation [39]
Ser 104 and 106 TPA-dependent trancription activation [40]
Ser 118 p42/p44 MAPK; CDK7 E2 and Tamoxifen-dependent ER activation [41]
Ser 118 CDK7 ligand-dependent interaction with TFIIH/CDK7 [42]
Ser 118 apo-ER transcriptional activation [43]
Ser 118 MAPK recruitment of p68 helicase [44]
Ser 104, 106, 118 MAPK ligand-dependent dimerization [45]
Ser 104, 106, 118 MAPK ER mRNA splicing [46]
Ser 104, 106, 118 growth factors ligand-dependent and independent binding to p160 coactivators [47]
Ser 154 unknown unknown [28]
Ser 167 casein kinase II activation of unliganded receptor [48]
Ser 167 p90 ribosomal S6 kinase 2 (Rsk2) activation of unliganded ER [49]
Ser 167 Akt, MAPK ligand-independent rapid signalling [50]
Ser 236 DBD PKA ER dimerization and DNA binding [51]
Ser 236 PKA ligand-mediated receptor degradation [52]
Ser 305 LBD (AF-2) negative regulation of ER acetylation [29]
Ser 305 p21 kinase increased transactivation [53]
Ser 559 CK2 Transcription inhibition [54]
Thr 311 LBD p38 prot kinase and MEKK regulation nuclear export and inhibits p160 interactions [55]
Tyr 52, 219 c-Abl Transcription activation [56]
Tyr 537 LBD (AF-2) src cell proliferation [57–59]
Tyr 537 LBD (AF-2) MAPK hormone-independent ERA activation [60]
ERß phosphorylation
Ser 94, Ser 106 N-terminus (AF-1) Erk ubiquitination and degradation of unliganded ERb [61]
Ser 106,124 AKT activation unliganded receptor and SRC-1 interaction [62]
Ser 106,124 PKA ERb activation [63]
Ser255 hinge region AKT inhibits Erb activity by inhibiting CBP interaction [62]
ERα acetylation
Lysine 266; 268 p300 stimulates DNA-binding and ligand-dependent activity [30]
Lysine 299, 302, and 303 p300 diminishes response to agonists [31]
ERα methylation
Arg 260 [34]
Lysine 302 SET7methyltransferase ER stabilization [64]
ERα ubiquitylation
Lysines 302-534 Ligand-independent ubiquitination [65]
Residues 535–595 (lysine 581) Ligand-dependent ubiquitination and receptor degradation [35]
ERα sumoylation
Lysines 266; 268 hinge region PIAS1 and PIAS3 ligand-dependent activity [37]
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are a member of a large family of transcription factors that evolved
from ancestors that were unable to bind ligands [78] and relied on
other common regulatory signals like phosphorylation. Even today,
other nuclear receptors, in particular the estrogen receptor related
proteins, may lack natural endogenous ligands, suggesting that the
regulation of NR activities by alternative mechanisms is likely to be
functionally important.
The functional signiﬁcance of unliganded ER activation still
requires further investigation to be fully understood. The systematic,
comparative, analysis of the cistrome related to ER activity in different
cell systems after activation by PTM or interaction with estrogen will
clarify the role of these alternative ways to activate ER which plays a
role in the selection of targets [79].
3. ERα and ERβ: why two receptor for a single hormone?
Intracellular ER exists in two forms ERα and ERβ which are tran-
scribed from different genes, but have a strong structural similarities,
particularly in the DBD (97% amino acid identity) and HBD (56%
amino acid identity); lower homology is found in the A/B amino-
terminus (about 20% identity) [3]. The two ERs have different cellular
and tissue distribution and activities: studies with animals in which
each of the two receptors were ablated and with selective ERα and
ERβ ligands show that after 17β-estradiol (E2) activation the two ER
isoforms have a differential effect both at systemic and cellular level:
ERα is essential for reproductive development and functions whileERβ activity is more relevant in non-reproductive organs in spite of
the fact that its presence and activity in the granulosa cells which
contributes to provide full fertility to mice [5]. The mechanisms
responsible for these differential physiological effects are still matter
of study. It is well known, that despite similar in vitro E2 and DNA
binding properties, ERβ has a substantially lower transcriptional ac-
tivity than ERα [80,81]: the underlying mechanism for such dif-
ferences is not fully characterized, undoubtedly, the absence of a
strong AF-1 domain in the ERβ A/B domain may explain the lower
transcriptional capacity of this isoform. It was also proposed that ERβ
contains a repression domain within its amino-terminus lowering the
efﬁciency of this receptor protein [82].
In several cell systems the two isoforms are co-expressed, often
at concentrations which may be signiﬁcantly modiﬁed by physio-
pathological events [7,83]. Several studies have addressed the issue of
speciﬁcity of action of ERα and ERβ and questioned their ability to
recognize speciﬁc ERE binding sites in the homo- and hetero-dimeric
form [16,84]. A recent study on the genome-wide dynamics of ER
chromatin binding has ﬁnally provided a very helpful view on the
intracellular interactions of the two ER by demonstrating that each ER
subtypewhen present alone bindmost of the EREs available, butwhen
both are expressed there is a mutual competition restricting sig-
niﬁcantly the number of the sites shared and a shifting of each ER to
new sites. Interestingly, when co-expressed, ERα has a predominance
on ERβ because it occupies most of the common sites causing a major
shift of ERβ to novel EREs. A potential explanation for these ﬁndings
is associated to the different afﬁnities for the EREs of the ERα
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ERβ homodimers (lower afﬁnity), which increases the residence time
of ERα homodimers on its DNA target, however several studies
showed that each of the two isoforms associates preferentially with
different co-regulators, it is therefore conceivable that in each cell
system each isoform adopts a speciﬁc set of co-modulators to best
fulﬁll their cell speciﬁc functions [85,86].
Thus the differential expression of the two receptor isoforms may
constitute a mechanism for the modiﬁcation of the overall transcrip-
tional ability of ERs in response to estrogens: this view is in line with
the initial speculations of ERβ role as a modulator of ERα proliferative
action in speciﬁc tissues (e.g., mammary cells) [87]. More recently, the
ﬁnding that unliganded ERβ may interact SRC-1 inducing ligand-
independent transcription and has the tendency to reside on the DNA
bound to co-repressors [88] led to further speculations on the
differential responsibilities of the two receptor isoform within each
target cell. ERα would be the primary target for ﬂuctuating levels of
circulating estrogens, while ERβ could be a permissive regulator of
estrogen-responsive genes via ERE-independent nuclear/cytoplasmic
signaling pathways. However this further hypothesis does not take
into account the fact that also ERαmay be transcriptionally activated
in the absence of the ligand.
4. Achieving a cell-speciﬁcity of action
One of the most striking features of ERs is their wide distribution in
the mammalian organisms and the variety of functions fulﬁlled in each
cell system. So far, at least eight distinct mechanisms contributing to ER
diversiﬁcation of functions may be envisaged: 1) the epigenetic events
that select the EREs transcriptionally available in each cell system;2) the
cell-speciﬁc expression of the co-regulators and enzymes necessary for
ER activation/inactivation; 3) the stoichiometry of ERα and ERβ; 4) the
presence of truncated versions of ERs due to differential transcriptional
initiation at ER promoter or to alternative splicing; 5) the levels of
circulating estrogens; 6) the composition of circulating estrogens each
having a differential ability to induce a allosteric conformation of the
LBD; 7) the levels of paracrine or endocrine hormones other than
estrogens able to regulate ER transcriptional ability at the promoter of
each target gene; 8) the complexity of the promoter itself that may
signiﬁcantly alter the receptor actions. The number of combinations in
which these events may occur provides a clear picture of the potential
multiple outcomesof ERactivation andunderlines thedifﬁcultiesweare
encountering in the deﬁnition of efﬁcacious replacement therapieswith
either synthetic or natural estrogens.
Yet a question arises: if these receptors have so many disparate
functions why the ablation of one or both ERs is not lethal? In view of
the evolutionary age of these proteins we speculate that in less
evolved organisms ERs were common transcription factors activated
by the signaling of membrane receptors (growth factors, neurotrans-
mitter or cytokines receptors). During evolution, membrane receptors
might have acquired more specialized pathways for their intracellular
signaling, but ERs were maintained as salvage pathway. At the same
time, novel synthetic pathways evolved to generate ligands able to
bind ERs and to convert them into ligand-operated transcription
factors able to modulate novel target genes. How ERs gained the
control over reproduction, the most important of the biological
functions, has not been object of intense study so far. However, if we
believe that in multicellular organisms these proteins were originally
involved in the transduction of most signals regulating cell homeo-
stasis, we might speculate that the selection of ERs as regulator of
reproduction was favored by their ability to sense and respond to a
variety of homeostatic and metabolic signals. Because of that, ERs
were able to ensure that pregnancy occurred only under environ-
mental and metabolic favorable conditions. If this was the case, the
understanding of the evolutionary cues that favored the selection of
ER as the key element in reproduction might constitute a signiﬁcantadvancement in our insights on ER physiology and, consequently, in
our ability to conceive hormone replacement therapies (HRT) much
more efﬁcacious than those currently available [52].5. Could exogenous administration of estrogens ever substitute
for the ovarian functions?
In the ﬁeld of estrogen action, the assessment of the necessity and
usefulness of HRT remains as one of the most unanswered questions.
Clinical and epidemiological studies demonstrated that the natural or
surgical cessation of ovarian functions is associated with increased
risk of incidence of cardiovascular, skeletal, immune and neurological
pathologies [6–12]. However, to date, any attempt to reinstate the
beneﬁcial effects of the cyclic hormone production by HRT has not
provided the desired results [89]. The major obstacle encountered
with the administration of natural estrogens is associated with
excessive cell proliferation in reproductive organs. Indeed, HRT with
estrogenic compounds causes uterine hyperplasia and an increased
risk of mammary, uterine and ovarian cancer [90]. The ﬁnding that
synthetic estrogens such as tamoxifenwere able to bind ERs and cause
unique allosteric conformations enabling the receptor to interact
efﬁciently with the transcription machinery only in selected tissues
led to propose the use of these Selective Estrogen Receptor
Modulators (SERMs) for a safe hormone replacement therapy [91].
This initiated a race for the identiﬁcation of the wonder molecule able
to activate ER only in non-reproductive tissues thus sparing the
negative effects of HRT in the reproductive organs. Interestingly, none
of the synthetic molecules so far identiﬁed proved to be the so desired
magic bullet, generally because none of the molecules synthesized
proved to be antagonist uniquely in the reproductive organs.
More recently, to overcome the proliferative effects associated
with HRT, attempts were made to exploit the differential physiology
of the two ERs and to develop selective agonists for ERβ. The ERβ
selective agonists so far developed belong to three classes: the ﬁrst is
represented by ERB-041 (WAY-202041) which binds to ERβ much
better than ERα; the second derived from plants (MF101, nyasol and
liquiritigenin) bind similarly to both ERs, but activate transcription
only with ERβ; the third diarylpropionitrile which selectivity is due to
a combination of greater binding to ERβ and high transcriptional
activity. So far, the data available on the biological/pharmacological
activities of these compounds are too limited to draw any deﬁnitive
conclusion on their suitability for HRT.
The selective ERα and ERβ ligands are a very important tool to
decipher the roles of ERα and ERβ in different organs and to elucidate
how ligands, acting through either of the two ERs, can prevent or treat
various age- or sex-speciﬁc diseases. Appropriate clinical studies are
necessary to validate these compounds as agents for the prevention
and treatment of diseases [92].
Our group recently proposed a novel strategy aimed at the study of
HRT which is based on the selection of molecules able to mimic at the
systemic level the oscillatory state of ER activation observed in
healthy females in the reproductive age [93,94]. The availability of the
ERE-Luc reporter mouse enabled to follow temporally, by means of in
vivo imaging, ERs transcriptional activity at systemic level. This model
enabled to demonstrate that in each organ ER activity oscillates in
time with a periodicity of about 4 days that is independent from the
ovarian production of estrogens. In fact, in the various organs, ER
activity on the promoters of the reporter as well as of endogenous
genes is asynchronous [69,94,95]; furthermore stress (e.g. calorie
restriction), or changes in the reproductive state (e.g. ovariectomy,
lactation, pregnancy) affect signiﬁcantly the extent of ER oscillatory
activity in terms of frequency and amplitude [94]. Altogether, these
observations suggest that factors other than circulating estrogen may
activate ERs and indicate that ER transcriptional activity adapts to the
overall state of animal health.
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controller because of its capacity to interact and react to most
homeostatic cues were true, we would predict that ovarian hormones
do not regulate ER activity, particularly in non-reproductive organs. In
reality, we would expect changes of ER activity in relation to
endogenous and exogenous signals affecting body homeostasis.
More research is needed to clarify how, in each organ, the changes
in the frequency of ER activity inﬂuence ER-dependent gene
expression programs and which are the hormonal cues networking
ER activity at systemic level. It is likely that an efﬁcacious HRT should
reproduce the ultracircadian ER oscillations typical of a healthy
cycling organism.
To verify the extent to which the oscillatory activity found in
healthy young fertile mice could be mimicked by the administration
of a synthetic estrogen, we performed a series of long term (21 days)
treatments of ovariectomized female mice with most of the known ER
ligands. The goal was therefore to assess whether any of these
treatments could reproduce a state of systemic ER activity comparable
to cycling mice. We demonstrated that each ligand was characterized
by a speciﬁc spatio-temporal proﬁle of ER transcriptional oscillations.
Further analysis of the data obtained by means of agglomerative
hierarchical clustering proved a strict correlation between the
structure of the compound tested and their effect on ER oscillation.
In addition, the clustering analysis allowed the identiﬁcation of
families of compound more likely to reproduce the effect of
endogenous hormones, thus paving the way to a novel methodology
to identify novel chemical entities suitable for HRT.
6. Conclusions
The results of the last years of study have demonstrated an
unsought complexity of ER action at both cellular and systemic level,
possibly providing an explanation for the difﬁculties found in the
design of appropriate HRT. These difﬁculties appear to be shared with
a number of other members of this important family of receptors
which revealed to be very complex targets for drugs, an example
being the PPAR ligands which revealed an unexpected amount of side
effects. The complexity of action of NR may require a revisitation of
the methodologies generally applied in drug discovery programs to
take into account the multiplicity of effects that ligands binding to NR
may induce at systemic level. From this standpoint the application of
in vivo imaging might provide novel opportunities of analysis
particularly for their ability to measure NR action in space and time
in living organisms [94].Acknowledgments
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